{"filing":{"accession_number":"0001171843-26-004253","cik":"0000898437","ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"f8k_062326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004253/f8k_062326.htm"},"events":[{"id":13143,"run_id":11664,"accession_number":"0001171843-26-004253","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Anika Therapeutics held its Annual Meeting on June 18, 2026, with stockholders voting on five proposals: election of three Class III directors (Fischetti, Henneman, Griffin), ratification of Deloitte \u0026 Touche LLP as auditor, advisory approval of named executive officer compensation, approval of the Revised Seventh Amended Plan increasing equity reserves, and amendment of the ESPP increasing share reserves. The filing reports the final voting results for each proposal.","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10207,"accession_number":"0001171843-26-004253","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder-approved amendments to two equity compensation plans: the 2017 Omnibus Incentive Plan (increasing authorized shares by 350,000) and the 2021 Employee Stock Purchase Plan (increasing authorized shares by 200,000). These are compensatory arrangements for officers and employees, directly falling under Item 5.02(e) and the exec_compensation category. The amendments expand the pool of equity available for grants and employee purchases, which is material to investors assessing the company's capital structure and executive compensation practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:00.045324+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10208,"accession_number":"0001171843-26-004253","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final results of Anika Therapeutics' Annual Meeting held June 18, 2026, including stockholder votes on five proposals: election of three Class III directors (Fischetti, Henneman, Griffin), ratification of Deloitte \u0026 Touche LLP as auditor, advisory approval of named executive officer compensation, approval of the Revised Seventh Amended Plan increasing equity reserves, and amendment of the ESPP increasing share reserves. The filing presents voting tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:00.045324+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10207,"accession_number":"0001171843-26-004253","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder-approved amendments to two equity compensation plans: the 2017 Omnibus Incentive Plan (increasing authorized shares by 350,000) and the 2021 Employee Stock Purchase Plan (increasing authorized shares by 200,000). These are compensatory arrangements for officers and employees, directly falling under Item 5.02(e) and the exec_compensation category. The amendments expand the pool of equity available for grants and employee purchases, which is material to investors assessing the company's capital structure and executive compensation practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:00.045324+00:00","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-06-23"},{"id":10208,"accession_number":"0001171843-26-004253","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final results of Anika Therapeutics' Annual Meeting held June 18, 2026, including stockholder votes on five proposals: election of three Class III directors (Fischetti, Henneman, Griffin), ratification of Deloitte \u0026 Touche LLP as auditor, advisory approval of named executive officer compensation, approval of the Revised Seventh Amended Plan increasing equity reserves, and amendment of the ESPP increasing share reserves. The filing presents voting tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:00.045324+00:00","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-06-23"}]}